ESR1 and neoplasm: They reported the presence of ESR1 mutations in 9 out of 60 (15%) FFPE samples and in 11 out of 80 (13.8%) circulating tumor DNA (ctDNA) samples from advanced and metastatic ovarian cancer patients.